Table 3 Univariable and multivariable analyses for discriminating iCCA and HCC in the high-risk population

Major features

 Tumor size (cm)^†

1.072 (0.957, 1.201)

0.230

 Non-rim APHE

0.038 (0.018, 0.079)

< 0.001

 Non-peripheral washout

0.022 (0.009, 0.052)

< 0.001

0.135 (0.027, 0.684)

0.016

 Enhancing capsule

0.009 (0.003, 0.024)

< 0.001

0.007 (0.001, 0.076)

< 0.001

LR-TIV

 Tumor in vein

0.151 (0.033, 0.691)

0.015

LR-M

 Any targetoid features

23.292 (11.405, 47.568)

< 0.001

 Rim APHE

13.068 (6.774, 25.208)

< 0.001

 Peripheral washout

3.058 (0.313, 29.873)

0.337

 Delayed central enhancement

6.220 (2.281, 16.961)

< 0.001

 Targetoid diffusion restriction

30.480 (10.468, 88.751)

< 0.001

 Infiltrative appearance

2.006 (0.910, 4.424)

0.084

 Marked diffusion restriction

0.772 (0.433, 1.374)

0.379

 Severe necrosis or ischemia

0.145 (0.079, 0.266)

< 0.001

0.156 (0.030, 0.826)

0.029

Ancillary features favoring HCC in particular

 Non-enhancing capsule

0.327 (0.033, 3.195)

0.337

 Nodule-in-nodule

0.159 (0.019, 1.342)

0.091

 Mosaic architecture

0.027 (0.004, 0.200)

< 0.001

 Fat in mass, more than adjacent liver^†

/

0.999

 Blood products in mass

0.027 (0.006, 0.116)

< 0.001

0.012 (0.000, 0.442)

0.016

Ancillary features favoring malignancy, not HCC in particular

 US visibility as discrete nodule

0.389 (0.074, 2.048)

0.265

 Corona enhancement

1.759 (1.024, 3.022)

0.041

 Fat sparing in solid mass ^†

/

0.999

 Iron sparing in solid mass

0.242 (0.086, 0.679)

0.007

 Restricted diffusion

1.000 (0.062, 16.197)

0.999

 Mild-moderate T2 hyperintensity

1.306 (0.759, 2.245)

0.335